Trials / Completed
CompletedNCT00882687
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lifitegrast | Ophthalmic Solution |
| OTHER | Placebo | Ophthalmic Solution |
Timeline
- Start date
- 2009-04-24
- Primary completion
- 2009-05-10
- Completion
- 2009-05-10
- First posted
- 2009-04-16
- Last updated
- 2021-06-11
- Results posted
- 2017-02-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00882687. Inclusion in this directory is not an endorsement.